Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/3/2011

SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2011.

Cadence commercially launched OFIRMEV® (acetaminophen) injection, the first and only intravenous formulation of acetaminophen to be approved in the U.S., in January 2011. As of July 31, 2011, OFIRMEV had received formulary acceptance at over 1,150 hospitals, representing more than 50% of the targeted U.S. IV analgesic market opportunity for OFIRMEV. Cadence's launch execution has progressed from creating access to creating sales demand, as a result, sales of OFIRMEV have begun to accelerate. Second quarter net product revenue was $1.7 million, an increase of approximately 325% compared to the $0.4 million in net product revenue reported for the first quarter of the year.

During the second quarter, OFIRMEV was added to the formularies of a number of highly influential, community-based hospital networks and some of the most well-respected academic medical centers in the U.S. Additionally, the product was added to the U.S. Department of Defense's Joint Deployment Formulary, the core list of pharmaceutical products required for theater-level care of deployed military forces.

"I am pleased to report that as of June 30, over 1,200 institutions had placed an order for OFIRMEV. Additionally, at the end of the second quarter, nearly 60% of those accounts had placed multiple orders for OFIRMEV, representing a significant increase over the first quarter of this year, at which time only 36% of our customers had re-ordered the product," said Ted Schroeder, President and CEO of Cadence. "Thanks to strong demand by hospital physicians and tremendous exe
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
2. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
4. Cadence, Inc. Announces Major Expansion
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
7. Cadence, Inc. Expands Executive Team
8. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
10. Cadence Pharmaceuticals to Present at Two Investment Conferences in February 2011
11. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  Now that ... the Da Vinci S™ surgical robot, hospitals with robotic ... plans. They also need to see where they stand ... on the right patients? Have they adopted best practices ... surgery program in the future? ECRI Institute, ...
(Date:8/27/2015)... 2015   Proxsys Rx, the nation,s ... expanding its population health management services with ... care program for hospitals and health systems. ... with technology systems and pharmacy support services ... been mandated by Center for Medicare and ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... Sermo ( http://www.sermo.com/client ), the ... free Sermo Report titled, " FDA Committee Recommends Approval ... the introduction of an investigational oral antiplatelet treatment for ... of physicians feel that ticagrelor will likely affect the ...
... Inc. (OTC Bulletin Board: AEMD ), the ... disease and cancer, announced today that the Medanta Independent ... has approved a treatment program entitled: "Use of the ... with Standard of Care (SOC) Drug Therapy."  The Medicity ...
Cached Medicine Technology:Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients 2Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 2Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 3Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 4Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 5Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 6
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of ... music and good people, all for a good cause. In its second year, the ... once more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for those seeking to go deep sea diving. The act of recreational ... decompression sickness; for these reasons, it is vital that all recreational and professional ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to ... available for general use any time soon, according to educational website Surviving Mesothelioma. ... that received orphan drug designation for mesothelioma last week from the FDA, will now ...
(Date:8/28/2015)... ... 28, 2015 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Founded in 1924 and headquartered in Pittsburgh, Pennsylvania, ... their goals. Within the past 10 years, TJS Insurance Group has emerged as ...
(Date:8/28/2015)... ... , ... External Counterpulsation, also known as ECP or EECP, is a proven ... or ECP) machines with a full clinic licence to help people prevent and reverse ... people prevent and reverse heart disease through its evidence-based integrative approach to ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... , , , , ... and for the seventh consecutive year consumers can purchase FAT bastard ... of September and October, FAT bastard will donate 25 cents ... retail locations, up to $75,000. By the end of this year,s ...
... SAO PAULO, Aug. 13 , , ... quality and timely information, coupled with the application of new ... focus on how Thomson Reuters has overcome this challenge, successfully ... , , Renowned experts will discuss ...
... , ALLEGAN, Mich., Aug. 13 ... that its Board of Directors declared a quarterly dividend of ... of record on August 28, 2009. , ... supplier that develops, manufactures and distributes over-the-counter (OTC) and generic ...
... Scientists investigating the effects of cannabis on bone health have ... study has found that although cannabis could reduce bone strength ... of the bones, in later life. The team at ... naturally in the body, which can be activated by cannabis ...
... , , , ... SIAL ) today announced an agreement with Glycosan BioSystems ... matrix (ECM) for stem cell research. HyStem offers researchers flexibility ... in vivo conditions, optimizing stem cell proliferation and ...
... Aug. 13 Lilly MDR TB Partnership and Children ... the TB eradication in India. , , ... , Lilly MDR TB Partnership, with the ... the teen community with necessary resources to help reach out ...
Cached Medicine News:Health News:FAT bastard Wine Drives Breast Cancer Awareness for Seventh Consecutive Year 2Health News:Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry 2Health News:Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research 2Health News:Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research 3Health News:'Eli Lilly-Children International' Launches Teen Campaign to Reduce TB Cases in India 2Health News:'Eli Lilly-Children International' Launches Teen Campaign to Reduce TB Cases in India 3
... Cepheid Smart GBS test, performed on ... in vitro diagnostic test designed to ... in vaginal/rectal specimens using proven real-time ... LIM broth cultures, Smart GBS delivers ...
...
... primers and a FAM-labeled probe that is ... In addition, this ASR contains primers and ... processing control. This ASR requires an instrument ... reporter dyes such as the Cepheid SmartCycler ...
... Protection Device features the ability to use ... lesion and a pre-loaded nitinol filter with ... Offering a fully rapid exchange system, the ... the indicated applications:, Carotid Indication - ,The ...
Medicine Products: